Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance.
Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance.
复制标题
DOI:
10.3390/biomedicines10051130
复制
发表时间:
2022-05-13
期刊:
影响因子:
4.7
通讯作者:
中科院分区:
文献类型:
--
作者:
Immune checkpoint blockades (ICBs) have revolutionized cancer treatment. Recent studies have revealed a subset of triple-negative breast cancer (TNBC) to be considered as an immunogenic breast cancer subtype. Characteristics of TNBC, such as higher mutation rates and number of tumor-infiltrating immune cells, render the immunogenic phenotypes. Consequently, TNBCs have shown durable responses to ICBs such as atezolizumab and pembrolizumab in clinic. However, a significant number of TNBC patients do not benefit from these therapies, and mechanisms of resistance are poorly understood. Here, we review biomarkers that predict the responsiveness of TNBCs to ICB and recent advances in delineating molecular mechanisms of resistance to ICBs.
登录
查看更多内容
影响因子:
8.8
作者:
Corrales L;Glickman LH;McWhirter SM;Kanne DB;Sivick KE;Katibah GE;Woo SR;Lemmens E;Banda T;Leong JJ;Metchette K;Dubensky TW Jr;Gajewski TF
通讯作者:
Gajewski TF
影响因子:
11.2
作者:
Falvo, Paolo;Orecchioni, Stefania;Bertolini, Francesco
通讯作者:
Bertolini, Francesco
影响因子:
50.3
作者:
Costa, Ana;Kieffer, Yann;Mechta-Grigoriou, Fatima
通讯作者:
Mechta-Grigoriou, Fatima
影响因子:
64.5
作者:
Ciriello G;Gatza ML;Beck AH;Wilkerson MD;Rhie SK;Pastore A;Zhang H;McLellan M;Yau C;Kandoth C;Bowlby R;Shen H;Hayat S;Fieldhouse R;Lester SC;Tse GM;Factor RE;Collins LC;Allison KH;Chen YY;Jensen K;Johnson NB;Oesterreich S;Mills GB;Cherniack AD;Robertson G;Benz C;Sander C;Laird PW;Hoadley KA;King TA;TCGA Research Network;Perou CM
通讯作者:
Perou CM
影响因子:
3.8
作者:
Bates JP;Derakhshandeh R;Jones L;Webb TJ
通讯作者:
Webb TJ